Gelonghui, January 30丨Oriental Biotech (688298.SH) announced the 2023 annual results forecast loss announcement. According to preliminary estimates by the finance department, it is expected to achieve net profit of 38,0000 million yuan in 2023, which will result in a loss. At the same time, compared with the net profit of 206,771.43 million yuan (statutory disclosure data), the net profit attributable to owners of the parent company in the previous year is expected to decrease by 244,7714,300 yuan, a year-on-year decrease of 118.38%.

According to preliminary estimates by the finance department, it is estimated that net profit of 424.00 million yuan after deducting non-recurring profit and loss attributable to owners of the parent company in 2023 will result in a loss; at the same time, compared with net profit of 208.92558 million yuan after deducting non-recurring profit and loss attributable to owners of the parent company in the previous year, it is estimated to decrease by 2513.255,800 yuan, a decrease of 120.29% from the previous year.